Biotechnology

Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...

2026-04-24 21:00 2712

Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy

* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...

2026-04-24 20:00 3241

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...

2026-04-24 19:30 2637

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...

2026-04-24 19:03 2807

CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair

Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...

2026-04-24 14:58 2830

Servier completes the acquisition of Day One Biopharmaceuticals

* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma.  * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs.  * Transaction represents total equity ...

2026-04-23 20:30 3604

Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing "China Solution" and Winning Three Major Awards

JAKARTA, Indonesia, April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth Asia-Pacific Awards 2026 at the Grand Hyatt Jakarta, joining a distinguished community of healthcare...

2026-04-23 16:46 3492

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...

2026-04-23 16:22 4488

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...

2026-04-23 15:02 1253

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...

2026-04-23 15:00 3300

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug P...

2026-04-23 14:14 3029

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in...

2026-04-23 11:37 2619

BioEngine Launches UltraFeed CHO Supplement, Boosting Titers by Up to 48%

SHANGHAI, April 23, 2026 /PRNewswire/ -- Shanghai BioEngine Sci-tech Co., Ltd. announced the launch of UltraFeed, a next-generation fed-batch supplement designed to elevate CHO cell productivity in monoclonal antibody, bispecific, and recombinant protein manufacturing. Across diverse cell lines a...

2026-04-23 09:17 2919

Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations

SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...

2026-04-23 06:30 3970

GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists

PISCATAWAY, N.J., April 23, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been ...

2026-04-23 04:03 1892

Samsung Biologics Reports First Quarter 2026 Financial Results

* Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion * Performance driven by full utilization across Plants 1 through 4 and robust operational execution * Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEO...

2026-04-22 14:50 3492

AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore

SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a c...

2026-04-22 14:13 3539

Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA

BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...

2026-04-22 11:09 2612

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now actively dosing participants — CHICAGO, April 2...

2026-04-22 10:10 3640

SynbioTech's L. plantarum FS4722 Emerges as a Potential Preventive Approach for Hyperuricemia

TAIPEI, April 22, 2026 /PRNewswire/ -- SynbioTech announced that its Lactiplantibacillus plantarum FS4722 (L. plantarum FS4722), a probiotic strain isolated from traditional Chinese pickled vegetables, has demonstrated potential to support urate regulation in hyperuricemia. L. plantarum FS4722 h...

2026-04-22 09:30 2859
1 ... 3456789 ... 349